NCIC CLINICAL TRIALS GROUP

BRAIN

DISEASE SITE COMMITTEE MEETING

AGENDA

OPEN SESSIONS

Venue: Carlyle
Date: Saturday, May 1st 2011
Time: 8:30 a.m. – 12:00 p.m.
Chair: Dr. Warren Mason

8:30 am  WELCOME AND INTRODUCTIONS  W. Mason

NEW CONCEPTS/PROPOSALS FOR ENDORSEMENT

8:35 am   ECOG E3F05: Phase III study of radiotherapy +/- temozolomide for symptomatic or progressive low-grade gliomas  D. Schiff (ECOG)

9:00 am   NCCTG N107C: A phase III trial of post-surgical stereotactic radiosurgery compared with whole brain radiotherapy (WBRT) for resected metastatic brain disease  P. Brown (NCCTG)

COMPLETED STUDIES

9:30 am   IND.162: A Phase I/II study of Temozolomide and RAD001c in Patients with Malignant Glioblastoma Multiforme Final report and manuscript status  W. Mason

TRIALS CLOSED TO ACCRUAL

9:40 am   CE5 (EORTC 22033-26033): Primary Chemotherapy with Temozolomide vs Radiotherapy in Patients with Low-Grade Gliomas After Stratification for Genetic 1P Loss: A Phase III Study  W. Mason

CE.5S: The Socio/behavioural Effects of Primary Chemotherapy with
Temozolomide vs Radiotherapy in Patients with Low-Grade Gliomas After Stratification for Genetic 1P Loss: A Phase III Study

A. Leis & M. Parkinson

Brain Disease Site Committee Learning Objectives

- To understand and address, through clinical and translational research, the disease burden associated with CNS malignancies Canada.

- To summarize recent developments in the understanding of molecular biology and therapeutics as these relate to CNS malignancies.

- To cite and analyze recent results of clinical studies conducted by or in collaboration with NCIC Clinical Trials Group relevant to CNS malignancies.

- To understand and apply new clinical trial methodologies in the field of clinical research in CNS malignancies.
**Brain Disease Site Agenda**

**Spring 2011**

**actively accruing trials**

9:50 am  **CE.6: A Randomized Phase III Study of Temozolomide and Short-Course Radiation versus Short-Course Radiation Alone in the Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients**

N. Laperriere & J. Perry

10:00 am  **coffee break**

10:15 am  **CEC.1 (EORTC 26053_22054): Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19Q Deleted Anaplastic Glioma. The CATNON Intergroup Trial**

W. Mason & C. O’Callaghan

10:30 am  **CEC.2 (NCCTG N0577): Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma (CODEL Trial)**

G. Cairncross & C. O’Callaghan

10:45 am  **IND.204: PX866 in Recurrent GBM**

M. Pitz

**special session - Terry Fox Research Institute (TFRI) Proposal: Therapeutic Targeting of GBM**

11:00 am  **Project Overview**

G. Cairncross

11:10 am  **Translational Research Program**

A. Luchman

11:40 am  **Role of NCIC CTG Brain and IND sites in conducting early phase clinical trials of promising new drugs for GBM**

E. Eisenhauer & W. Mason

12:00 p.m.  **Closing Remarks**

**Brain Disease Site Committee Learning Objectives**

- To understand and address, through clinical and translational research, the disease burden associated with CNS malignancies Canada.
- To summarize recent developments in the understanding of molecular biology and therapeutics as these relate to CNS malignancies.
- To cite and analyze recent results of clinical studies conducted by or in collaboration with NCIC Clinical Trials Group relevant to CNS malignancies.
- To understand and apply new clinical trial methodologies in the field of clinical research in CNS malignancies.